GBT’s drug meets trial goal, investors skeptical of speedy approval
By Manas Mishra and Tamara Mathias (Reuters) – Global Blood Therapeutics Inc’s sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated...
Read More